conventional-dose ticagrelor — Competitive Intelligence Brief

conventional-dose ticagrelor (conventional-dose ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist. Area: Cardiovascular.

phase 3 P2Y12 receptor antagonist P2Y12 receptor Cardiovascular Small molecule

Target snapshot

conventional-dose ticagrelor (conventional-dose ticagrelor) — First Affiliated Hospital of Harbin Medical University. Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
conventional-dose ticagrelor TARGET	conventional-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	phase 3	P2Y12 receptor antagonist	P2Y12 receptor
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)
Aspirin + Ticagrelor	Aspirin + Ticagrelor	The First Affiliated Hospital with Nanjing Medical University	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (ticagrelor)
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist class)

1. First Affiliated Hospital of Harbin Medical University · 4 drugs in this class
2. Fu Wai Hospital, Beijing, China · 1 drug in this class
3. Ping-Yen Liu · 1 drug in this class
4. Samsung Medical Center · 1 drug in this class
5. St. Antonius Hospital · 1 drug in this class
6. University of Florida · 1 drug in this class